Nov 7, 2022 4:05 pm EST Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
Nov 4, 2022 4:30 pm EDT Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
Nov 2, 2022 8:09 am EDT Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Oct 24, 2022 8:56 am EDT Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Oct 7, 2022 7:00 am EDT Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Oct 6, 2022 9:27 am EDT Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Sep 29, 2022 8:00 am EDT Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Sep 27, 2022 7:30 am EDT Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Sep 15, 2022 7:00 am EDT Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Sep 12, 2022 8:34 am EDT Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference